noom glp-1 microdose Microdosing Reshapes Weight Loss Noom introduces longevity-focused GLP-1 microdosing
Description
Liver Health GLP-1s at low doses showed real promise for liver health
Furthermore, long-term studies focusing on safety, efficacy, and patient-specific factors will be essential to translate these innovations into viable therapeutic options
10.1016/j.jhepr.2024.101271 33 GalassoL.CerritoL.MaccauroV.TermiteF.MigniniI.EspostoG.et al (2024)
Author Contributions All authors have reviewed the final manuscript prior to submission
Molecular and Cellular Endocrinology, 439 , 1015
3.3.4 Polyethylene glycol loxenatide The early GLP-1R agonist has many defects, such as multiple injections and a high incidence of adverse reactions in the digestive tract, which limits its clinical application
